Evidence map›Paper›PMID 31433803›Full record

ArticlePloS one2019

Understanding acceptance of and adherence to a new formulation of paediatric antiretroviral treatment in the form of pellets (LPV/r)-A realist evaluation.

Ariadna Nebot Giralt, Christiana Nöstlinger, Janice Lee, Olawale Salami, Marc Lallemant, Washington Onyango-Ouma, Isaac Nyamongo, Bruno Marchal

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Ariadna Nebot GiraltDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Christiana NöstlingerDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Janice LeeDrugs for Neglected Diseases Initiative, Geneva, Switzerland.
Olawale SalamiDrugs for Neglected Diseases Initiative, Nairobi, Kenya.
Marc LallemantDrugs for Neglected Diseases Initiative, Geneva, Switzerland.
Washington Onyango-OumaInstitute of Anthropology, Gender and African Studies, University of Nairobi, Museum Hill, Nairobi, Kenya.
Isaac NyamongoInstitute of Anthropology, Gender and African Studies, University of Nairobi, Museum Hill, Nairobi, Kenya.
Bruno MarchalDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0001-7185-022X
Instituut voor Tropische Geneeskunde · BEDrugs for Neglected Diseases Initiative · CHUniversity of Nairobi · KEKenya AIDS Vaccine Initiative · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImproving access to paediatric HIV treatment requires large-scale antiretroviral treatment programmes and medication adapted to infants and children's needs. The World Health Organisation recommends lopinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors as first-line treatment for all HIV-infected children younger than three years, usually given as a syrup. A pellet formulation (i.e. tiny cylinders of compressed medication put in capsules) was developed to overcome the syrup formulation's disadvantages such as bitterness, toxicity and cold storage. This study assessed multi-level factors influencing caregivers' acceptance of and adherence to lopinavir/ritonavir pellets as well as their underlying mechanisms.

methodsA realist evaluation (a theory-driven evaluation method considering the social context and mechanisms of change), embedded in a clinical trial was carried out in three hospital settings in Kenya. Data were collected through document review, observations (n = 34) in home and clinic settings and semi-structured interviews (n = 44) with caregivers and providers. Data analysis was based on realist principles.

resultsHigh levels of treatment initiation and adherence were observed. Taste masking, neutral packaging and easy storage made the new formulation highly acceptable. Caregivers developed individual strategies to deliver the treatment, particularly to overcome specific problems e.g. in case of just-weaned babies or food shortage. A refined program theory emerged from the triangulated findings showing that ease of administration combined with increased self-efficacy and competences of the caregivers, and effective provider support contributed to high levels of adherence.

conclusionsFormulating combined antiretroviral treatment in the form of pellets is clearly a more acceptable solution for infants and children and their caregivers compared to the syrup. Further research in non-trial settings may shed light on factors related to providers, services and the health system that contribute to better adherence of such formulations.

Indexed as

CaregiversPatient Acceptance of Health CareAnti-HIV AgentsAnti-Retroviral AgentsChild, PreschoolDrug ImplantsFemaleHIV InfectionsHumansInfantLopinavirMaleRitonavirViral LoadAnti-HIV AgentsAnti-Retroviral AgentsDrug ImplantsLopinavirRitonavir

Identifiers

PMID31433803
PMCPMC6703671
OpenAlexW2969349636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.